Hudson et al. [22] reported that levels of miR-375’s potential downstream targets, YAP1 and SLC16a2 were reduced in MTC, suggesting miR-375 could function as a negative regulator of YAP1 and SLC16a2. The gene discussed is SLC16A2; the disease is medullary thyroid gland carcinoma.